1. Key Takeaways From Relay Therapeutics Analyst Ratings

    By Benzinga Insights Ratings for Relay Therapeutics (NASDAQ: RLAY ) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 day
  2. Merck Commences P-III Study of MK-1084 Plus Keytruda as a Treatment of Metastatic Non-Small Cell Lung Cancer

    By PharmaShots Shots: Merck has commenced the P-III clinical evaluation of MK-1084 + Keytruda vs Keytruda + PBO in treatment-naïve KRAS G12C-mutated metastatic NSCLC patients (n=600) having PD-L1 TPS ≥50% with 1EPs as PFS & OS as well as 2EPs include ORR & DoR The company is asses
  3. Immuneering Reports First Patient Dosing with IMM-6-415 in the P-I/IIa Study for Treating Advanced Solid Tumors

    By PharmaShots Shots: Immuneering has dosed the first patient with IMM-6-415 in the P-I/IIa clinical evaluation for the treatment of advanced solid tumors associated with RAF or RAS mutations The P-I/IIa dose escalation and expansion study assesses the safety, tolerability, PK/PD
  4. PharmaShots Magazine - March 2024 Edition

    By PharmaShots Every month PharmaShots explores a new theme to add character and depth to our magazine. March 2024 edition is exploring Precision medicine as a theme. Imbued with curated themes delving deep into assorted segments designed to keep you hooked throughout the magazine
  5. Scientists discover sources of Parkinson’s, Tourette’s syndrome, and OCD in bombshell disease study

    By Yelena Mandenberg A revolutionary study by a team of scientists at Mass General Brigham revealed a path to target the sources of common brain disorders - which may one day be used to stop them altogether. Scientists used Deep Brain Stimulation (DBS), to "pinpoint dysfunctions in
  6. A New Pathway to Parkinson’s Treatments

    For over two centuries since James Parkinson first described the disease that now bears his name, improving lives impacted by Parkinson’s has been a challenge. While medications provide relief from motor symptoms, non-motor issues are harder to address. Now, fresh insight into an
  7. $IDYA +26% - 🔬 IDEAYA Biosciences announces promising interim results from their Phase 2 trial evaluating darovasertib and crizotinib combo in metastatic uveal melanoma (MUM) patients, with ORR of 45% and median PFS of ~7 months in First-Line MUM. This potential paradigm shift i